Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering.
Genenta is engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. Its lead candidate, Temferon, was developed using its novel biologic platform and carries interferon-alpha (IFN-α), a well-known therapeutic that was previously administered intravenously for treatment of various cancers but is currently rarely used due to its systemic toxicity. The company is currently developing Temferon for glioblastoma multiforme (GBM) in patients with GBM who have an unmethylated MGMT gene promoter (uMGMT), and is currently conducting a Phase 1/2a dose-escalation trial in newly diagnosed uMGMT-GBM patients in Italy. Genenta anticipates completing patient enrollment and treatment by the 2Q22, and as of October 15, 2021, its has administered Temferon to a total of 15 patients.
The Milan, Italy-based company was founded in 2014 and plans to list on the Nasdaq under the symbol GNTA. Genenta Science filed confidentially on March 1, 2021. Roth Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
